JP2024525566A5 - - Google Patents

Info

Publication number
JP2024525566A5
JP2024525566A5 JP2024500249A JP2024500249A JP2024525566A5 JP 2024525566 A5 JP2024525566 A5 JP 2024525566A5 JP 2024500249 A JP2024500249 A JP 2024500249A JP 2024500249 A JP2024500249 A JP 2024500249A JP 2024525566 A5 JP2024525566 A5 JP 2024525566A5
Authority
JP
Japan
Prior art keywords
approximately
cancer
pharmaceutical composition
composition according
sucrose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024500249A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024525566A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/034493 external-priority patent/WO2023283049A1/en
Publication of JP2024525566A publication Critical patent/JP2024525566A/ja
Publication of JP2024525566A5 publication Critical patent/JP2024525566A5/ja
Pending legal-status Critical Current

Links

JP2024500249A 2021-07-09 2022-06-22 Pd‐1抗体の医薬組成物及びその使用 Pending JP2024525566A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163220006P 2021-07-09 2021-07-09
US63/220,006 2021-07-09
PCT/US2022/034493 WO2023283049A1 (en) 2021-07-09 2022-06-22 Pharmaceutical compositions of a pd-1 antibody and use of the same

Publications (2)

Publication Number Publication Date
JP2024525566A JP2024525566A (ja) 2024-07-12
JP2024525566A5 true JP2024525566A5 (cg-RX-API-DMAC10.html) 2025-06-30

Family

ID=82608118

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024500249A Pending JP2024525566A (ja) 2021-07-09 2022-06-22 Pd‐1抗体の医薬組成物及びその使用

Country Status (17)

Country Link
US (2) US12364756B2 (cg-RX-API-DMAC10.html)
EP (1) EP4366692A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024525566A (cg-RX-API-DMAC10.html)
KR (1) KR20240035533A (cg-RX-API-DMAC10.html)
CN (1) CN118215465A (cg-RX-API-DMAC10.html)
AR (1) AR126404A1 (cg-RX-API-DMAC10.html)
AU (1) AU2022307332A1 (cg-RX-API-DMAC10.html)
CA (1) CA3224640A1 (cg-RX-API-DMAC10.html)
CL (1) CL2024000077A1 (cg-RX-API-DMAC10.html)
CO (1) CO2024000198A2 (cg-RX-API-DMAC10.html)
CR (1) CR20240065A (cg-RX-API-DMAC10.html)
EC (1) ECSP24008791A (cg-RX-API-DMAC10.html)
IL (1) IL309985A (cg-RX-API-DMAC10.html)
MX (1) MX2024000268A (cg-RX-API-DMAC10.html)
PE (1) PE20240797A1 (cg-RX-API-DMAC10.html)
TW (1) TW202308694A (cg-RX-API-DMAC10.html)
WO (1) WO2023283049A1 (cg-RX-API-DMAC10.html)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2476934C (en) * 2002-02-27 2009-06-16 Immunex Corporation Stabilized tnfr-fc composition comprising arginine
PE20231958A1 (es) * 2015-07-30 2023-12-06 Macrogenics Inc Moleculas de union a pd-1 y metodos de uso de las mismas
JOP20190260A1 (ar) * 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
EP3705134A4 (en) * 2017-11-02 2021-07-28 Nanjing Shunxin Pharmaceutical Co., Ltd. PHARMACEUTICAL COMPOSITION CONTAINING A HUMANIZED MONOCLONAL ANTIBODY ANTI-PD-L1
IL277095B2 (en) * 2018-03-07 2025-10-01 Pfizer Preparations containing anti-PD-1 antibody
CN110404066B (zh) * 2018-04-28 2022-06-17 齐鲁制药有限公司 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途
WO2021022172A1 (en) 2019-08-01 2021-02-04 Incyte Corporation A dosing regimen for an ido inhibitor
CN114206386A (zh) 2019-08-05 2022-03-18 小野药品工业株式会社 免疫检查点抑制剂的有效性判定生物标记

Similar Documents

Publication Publication Date Title
JP6141958B2 (ja) 増殖性疾患の治療のための併用療法(ベムラフェニブ及びmdm2阻害剤)
JP2014132009A5 (cg-RX-API-DMAC10.html)
JP2022533578A5 (cg-RX-API-DMAC10.html)
JP2012500180A5 (cg-RX-API-DMAC10.html)
ES2899636T3 (es) Tinostamustina para su uso en el tratamiento de cáncer de ovario
WO2019096194A1 (zh) Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途
CN115624550B (zh) 一种用于治疗胃癌的喹啉衍生物
US20080193448A1 (en) Combinations and Methods of Using an Indolinone Compound
TWI762784B (zh) Cdk4/6抑制劑與egfr抑制劑聯合在製備治療腫瘤疾病的藥物中的用途
WO2025157289A1 (zh) 包含prmt5抑制剂和krasg12c抑制剂的药物组合物
WO2019057141A1 (zh) 阿帕替尼和c-Met抑制剂联合在制备治疗肿瘤的药物中的用途
WO2022052874A1 (zh) 西奥罗尼联合免疫检查点抑制剂在抗肿瘤治疗中的应用
JP2024513575A (ja) Fgfr阻害剤及びネクチン-4標的化剤を含む併用療法
JP2023513297A5 (cg-RX-API-DMAC10.html)
WO2023134706A1 (zh) 抗trop-2抗体偶联药物和其他治疗剂的组合用途
ES2685974T3 (es) Derivados de cefalosporina para tratar el cáncer
CN103370066A (zh) 用于治疗癌症的包含威罗菲尼和干扰素的组合疗法
JP2022519923A5 (cg-RX-API-DMAC10.html)
JP6063472B2 (ja) 骨髄増殖性新生物形成および慢性骨髄性白血病を含む、トランスデューシンβ様タンパク質1(TBL1)活性に関連する疾患および障害の処置のための方法
US20220062294A1 (en) Pharmaceutical compositions of tetracyclic quinolone analogs and their salts
JP2016520665A (ja) Mps−1キナーゼ阻害剤および有糸分裂阻害剤を含む、癌の治療のための組合わせ
ES2330324T3 (es) Derivados del epotilon para el tratamiento del hepatoma y de otros canceres.
JP7381115B2 (ja) 組成物及びがん治療用医薬品の調製におけるその応用
WO2020236668A1 (en) Leukadherin-1 alone or in combination for use in the treatment of cancer
Hotte et al. Final results of a phase I/II study of CTCE-9908, a novel anticancer agent that inhibits CXCR4, in patients with advanced solid cancers